Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585846 | 0.94 | CYP3A4 (0.36) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL585869 | 0.82 | SMN1; SMN2 (0.42) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL78319 | 0.81 | CYP3A4 (0.36) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL3184954 | 0.76 | CYP3A4 (0.44) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL586749 | 0.75 | CA2 (0.33) | ALDH1A1CA2 | |
| SCHEMBL937756 | 0.75 | SMN1; SMN2 (0.42) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL585549 | 0.75 | SMN1; SMN2 (0.38) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL77412 | 0.74 | SMN1; SMN2 (0.48) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL8859882 | 0.72 | SMN1; SMN2 (0.39) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 | |
| SCHEMBL940460 | 0.72 | SMN1; SMN2 (0.39) | CYP2D6CYP3A4SMN1; SMN2ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343886-B2 | Polymerization modifiers | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110196117-A1 | POLYMERIZATION MODIFIERS | Dow Global Technologise LLC (US) | 2011-08-11 | — | — | US | disclosed |
| US-20060014633-A1 | Catalyst compositon for olefin polymerization | SCHOTTENBERGER HERWIG | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196117-A1 | POLYMERIZATION MODIFIERS | ALOX12, MYB, ALOX5 | CYP2D6 2258/4885CYP3A4 1099/4885SMN1; SMN2 4024/4885 |
| US-20060014633-A1 | Catalyst compositon for olefin polymerization | C1S, C1R, C1QBP | CYP2D6 1177/4885CYP3A4 853/4885SMN1; SMN2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.